CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN's technology platform, Opti…
CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN's technology platform, Opti…
Mindpeak announces the CE-mark for another new product: Mindpeak Breast HER2 RoI (Region of Interest) supports pathologi…
Paige, the global leader in AI-based diagnostic software in pathology, and Mindpeak, the European leader for AI-based so…
The demand for hyperbaric oxygen therapy devices has been increasing significantly with rising prevalence of wound infec…
BITZER Digital Network (BDN) is an online platform based on BITZER’s refrigeration know-how and data analytics helping t…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
Bladder Cancer Market - Segmentation By type, the global bladder cancer market has been segmented into transitional cel…
. Bladder Cancer Market - Segmentation By type, the global bladder cancer market has been segmented into transitional…
Future Market Insights (FMI) delivers key insights on the global hyperbaric oxygen therapy devices market in its upcomin…